Serum-Free Progenitor T Cell Generation Using DL4 and VCAM-1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human progenitor T cells in vitro are hindered by the use of undefined and xenogeneic systems, such as serum-containing media and murine OP9 feeders, which limit clinical translation and skew T cell development, with no reported defined system for T cell development.
Innovation Solution
A method involving the culture of stem and/or progenitor cells with Delta-like-4 (DL4) and vascular adhesion molecule 1 (VCAM-1) under serum-free conditions to generate progenitor T cells, using immobilized DL4 and VCAM-1 in a defined medium, promoting Notch signaling and T cell differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If serum-containing medium and murine OP9 feeders are used for T cell development, then T cell differentiation can be achieved, but the system becomes undefined and xenogeneic, limiting clinical translation
Solution Approach 1:
The invention extracts and eliminates the xenogeneic OP9 feeder layer and undefined serum components from the culture system. By removing these problematic elements and replacing them with defined human stromal cells and chemically defined media, the system achieves both T cell differentiation capability and clinical translatability.
Solution Approach 2:
The invention introduces human stromal cells as an intermediary component that provides the necessary support functions for T cell development without introducing xenogeneic elements. These human stromal cells serve as a bridge between the culture system and clinical application, maintaining differentiation capability while ensuring compatibility.
2Ease of manufacture
If OP9 feeder layer is used for Notch signaling, then T cell development is supported, but the system skews toward non-T (B lineage) cells
Solution Approach 1:
The invention applies local quality by using human stromal cells with specific characteristics optimized for T cell development. These cells provide localized Notch signaling and other supportive functions specifically tailored for T lineage commitment, preventing skewing toward B lineage while maintaining the necessary differentiation support.
3Reliability
If a defined serum-free system is implemented, then clinical translatability is improved, but T cell development efficiency may be reduced
Solution Approach 1:
The invention changes the parameters of the culture system by using chemically defined media with controlled concentrations of growth factors and cytokines. This allows optimization of T cell development efficiency within the defined system, achieving both clinical translatability and productive output through precise parameter control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the generation of progenitor T cells with enhanced purity and efficiency, achieving comparable yields to traditional systems while avoiding the limitations of serum and xenogeneic components, and supports the differentiation of human progenitor T cells into mature T cells.
Implementation Method 1
promoting Notch signaling and T cell differentiation
Implementation Method 2
using immobilized DL4 and VCAM-1 in a defined medium
Data Source
AI summary
The present disclosure provides a method for generating progenitor T cells from stem and/or progenitor cells comprising exposing the stem and/or progenitor cells to Notch ligand Delta-like-4 (DL4) and vascular adhesion molecule 1 (VCAM-1) under conditions suitable to generate progenitor T cells. The method provided is suitable for in vitro and in vivo pro-T cell generation. In vitro, the pro-T cells are generated under serum-free conditions. Cells produced using the method are provided as well as methods of using same.